Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Public access defibrillators

This article was originally published in The Gray Sheet

Executive Summary

HR 3462, the Community Access to Emergency Defibrillation Act of 2001 (Community AED Act) is introduced in the House Dec. 12 by Reps. Lois Capps (D-Calif.) and John Shimkus (R-Ill.). The bill authorizes more than $55 mil. a year for five years for communities to purchase automatic external defibrillators and to establish public access to defibrillation (PAD) programs. The measure is identical to S 1275, which was introduced July 31 by Sens. Edward Kennedy (D-Mass.) and Bill Frist (R-Tenn.). Staffers are cautiously optimistic that the bill could be hotlined for floor consideration in the next few weeks. AED manufacturer Medtronic VP-Corporate Controller Gary Ellis notes that its LifePak system direct-to-consumer advertising has helped to build awareness of the condition and its risk factors...

You may also be interested in...

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts